News Sentiment

BNTC sentiment intelligence

Benitec Biopharma Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.42 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+1.5% over one week, +20.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

(BNTC) and the Role of Price-Sensitive Allocations

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 1.5% Price digesting
Trend fit Trend active 20.0% over four weeks
Fair value 39.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 32
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 5
Stock Traders Daily 4
TradingView 4
TradingKey 4
dars.gov.et 4
Finviz 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 17
Guidance 6
Analyst action 2
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-46 of 46
Stock Titan Direct company coverage

Benitec Biopharma (BNTC) director David Friedman files initial Form 3

Benitec Biopharma Inc. director David Matthew Friedman has filed an initial Form 3, which is a regulatory disclosure of his ownership status as a director. This filing serves as a baseline and does not indicate any current shareholdings or recent transactions. The document confir

Tone
Neutral 50/100
Event
Regulatory and legal
Published
28 May 2026 19:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Benitec Biopharma (NasdaqCM:BNTC) Stock Forecast & Analyst Predictions

Benitec Biopharma (BNTC) is a gene therapy company focused on developing therapies for Oculopharyngeal Muscular Dystrophy (OPMD), with its lead asset BB-301 showing promising interim clinical results in Phase 1b/2a trials. Despite positive clinical data and projected revenue grow

Tone
Positive 61/100
Event
Earnings
Published
26 May 2026 20:40
Source
Simply Wall Street
Investing.com Direct company coverage

Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise

Benitec Biopharma (NASDAQ:BNTC) is a clinical-stage biotechnology company making progress with its lead gene therapy candidate, BB-301, for oculopharyngeal muscular dystrophy (OPMD), showing a 100% complete response rate in its Phase 1b/2a clinical study. The company recently sec

Tone
Positive 65/100
Event
Market update
Published
25 May 2026 22:40
Source
Investing.com
ChartMill Direct company coverage

BNTC News | BENITEC BIOPHARMA INC (NASDAQ:BNTC)

This page provides recent news and analysis for BENITEC BIOPHARMA INC (NASDAQ:BNTC), displaying the current stock price and links to detailed company information. It highlights two recent news items: a stock gain due to positive BB-301 data despite an earnings miss, and the relea

Tone
Positive 60/100
Event
Earnings
Published
19 May 2026 21:10
Source
ChartMill